A Phase 1 Trial of Image Guided Risk Volume-Adapted Postprostatectomy Radiation Therapy.
Autor: | Patel KR; Radiation Oncology Branch, National Cancer Institute, National Institutes fo Health, Bethesda, Maryland., Mena E; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Rowe LS; Department of Oncology, University of Alberta, Edmonton, Alberta, Canada., Ning H; Radiation Oncology Branch, National Cancer Institute, National Institutes fo Health, Bethesda, Maryland., Cheng J; Radiation Oncology Branch, National Cancer Institute, National Institutes fo Health, Bethesda, Maryland., Salerno K; Radiation Oncology Branch, National Cancer Institute, National Institutes fo Health, Bethesda, Maryland., Schott E; Radiation Oncology Branch, National Cancer Institute, National Institutes fo Health, Bethesda, Maryland., Nathan DA; Radiation Oncology Branch, National Cancer Institute, National Institutes fo Health, Bethesda, Maryland., Huang EP; Biometric Research Program, National Cancer Institute, National Institutes of Health, Rockville, Maryland., Lindenberg L; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Choyke P; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Turkbey B; Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Citrin DE; Radiation Oncology Branch, National Cancer Institute, National Institutes fo Health, Bethesda, Maryland. Electronic address: citrind@mail.nih.gov. |
---|---|
Jazyk: | angličtina |
Zdroj: | International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 Oct 09. Date of Electronic Publication: 2024 Oct 09. |
DOI: | 10.1016/j.ijrobp.2024.09.048 |
Abstrakt: | Purpose: This was a phase 1 trial with the primary objective of identifying the most compressed dose schedule (DS) tolerable using risk volume-adapted, hypofractionated, postoperative radiation therapy (PORT) for biochemically recurrent prostate cancer. Secondary endpoints included biochemical progression-free survival and quality of life (QOL). Methods and Materials: Patients were treated with 1 of 3 isoeffective DSs (DS1: 20 fractions, DS2: 15 fractions, and DS3: 10 fractions) that escalated the dose to the imaging-defined local recurrence (73 Gy Results: Between January 2018 and December 2023, 15 patients were treated (3 with DS1, 3 with DS2, and 9 with DS3). The median follow-up was 48 months. No dose-limiting toxicities were observed on any DS, and thus, expansion occurred at DS3. The cumulative incidence of G3 GI and genitourinary toxicity was 7% and 9% at 24 months, respectively, with no G4 events observed. Transient, acute G2+ GI toxicity was the most common. QOL worsened transiently during study follow-up in urinary incontinence, GI, and sexual subdomains but was similar to baseline by 24 months. The biochemical progression-free survival was 91% at both 24 and 60 months. Conclusions: The maximally tolerated hypofractionated DS for hypofractionated, risk volume-adapted PORT was determined to be DS3 (36.4 Gy to the prostate bed and 47.1 Gy to the imaging-defined recurrence in 10 daily fractions). No >G3 events were observed. Transient declines in QOL did not persist through 24 months. (Published by Elsevier Inc.) |
Databáze: | MEDLINE |
Externí odkaz: |